EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia

Christian Stirnkorb, Verena Ney, Carsten Bergmann, Martin Bald iD

Journal of Pediatric Endocrinology and Metabolism · 2025

DOI: 10.1515/jpem-2024-0505 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, 2025. Verfasst von Christian Stirnkorb und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Nephrology, Olga-Hospital, Clinic of Stuttgart, Stuttgart, Germany. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Blood Component Removal, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Investigation of the efficacy of the angiopoietin-like protein 3 (ANGPTL3) antibody evinacumab in a four-year-old infant with homozygous familial hypercholesterolemia (HoFH) as an adjunct to lipid apheresis. Case presentation A two-year-old boy was found to have xanthomas of the Achilles tendon and LDL cholesterol levels around 900 mg/dL. HoHF was subsequently confirmed by molecular genetics. At the age of three, lipid apheresis was started twice a week. At the age of four, a four-weekly infusion of evinacumab was started. This resulted in a 67 % reduction in LDL cholesterol before apheresis, allowing the frequency of apheresis to be reduced to once a week. The mean LDL concentration fell by a further 37 % despite the reduction in apheresis. With the addition of ezetimibe, the mean LDL concentration was reduced to below 115 mg/dL.

Conclusions

The administration of evinacumab can significantly lower the concentration of LDL cholesterol in infants and thus reduce the frequency of lipid apheresis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IIBlood Component RemovalAntibodies, MonoclonalHumansMaleChild, PreschoolHomozygoteCholesterol, LDLAngiopoietin-Like Protein 3Anticholesteremic AgentsPrognosis

Stichwörter der Autor:innen

evinacumabhomozygous familial hypercholesterolemialipid apheresis

Substanzen

evinacumabCholesterol, LDLAntibodies, MonoclonalAngiopoietin-Like Protein 3ANGPTL3 protein, humanAnticholesteremic Agents

Autor:innen und Institutionen

  • Department of Pediatric Nephrology, Olga-Hospital, Clinic of Stuttgart, Stuttgart, Germany.
  • Medizinische Genetik Mainz, Limbach Genetics, Mainz, Germany.

ORCID-Profile: Martin Bald

Zitieren

APA

Stirnkorb, C., Ney, V., Bergmann, C., & Bald, M. (2025). Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2024-0505

Vancouver

Stirnkorb C, Ney V, Bergmann C, Bald M. Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia. Journal of Pediatric Endocrinology and Metabolism. 2025. doi:10.1515/jpem-2024-0505

BibTeX
@article{Stirnkorb2025,
  author = {Stirnkorb, Christian and Ney, Verena and Bergmann, Carsten and Bald, Martin},
  title = {Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia},
  journal = {Journal of Pediatric Endocrinology and Metabolism},
  year = {2025},
  doi = {10.1515/jpem-2024-0505}
}
Kostenlos starten →